These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29737150)

  • 1. Pycnogenol® supplementation improves the control of irritable bowel syndrome symptoms.
    Belcaro G; Gizzi G; Pellegrini L; Feragalli B; Cotellese R; Cacchio M; Corsi M
    Panminerva Med; 2018 Jun; 60(2):65-69. PubMed ID: 29737150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Episodic primary migraine headache: supplementary prophylaxis with Pycnogenol® prevents attacks and controls oxidative stress.
    Cesarone MR; Dugall M; Hu S; Belcaro G; Hosoi M; Scipione V; Scipione C; Cotellese R
    Panminerva Med; 2020 Jun; 62(2):102-108. PubMed ID: 31670494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome®) controls symptoms of mild irritable bowel syndrome.
    Belcaro G; Gizzi G; Pellegrini L; Corsi M; Dugall M; Cacchio M; Feragalli B; Togni S; Riva A; Eggenhoffner R; Giacomelli L
    Eur Rev Med Pharmacol Sci; 2017 May; 21(9):2249-2254. PubMed ID: 28537656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The COFU3 Study. Improvement in cognitive function, attention, mental performance with Pycnogenol® in healthy subjects (55-70) with high oxidative stress.
    Belcaro G; Dugall M; Ippolito E; Hu S; Saggino A; Feragalli B
    J Neurosurg Sci; 2015 Dec; 59(4):437-46. PubMed ID: 26635191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics).
    Khalif IL; Quigley EM; Makarchuk PA; Golovenko OV; Podmarenkova LF; Dzhanayev YA
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):17-22. PubMed ID: 19337628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of mild, primary Raynaud Syndrome: supplementation with Pycnogenol®.
    Hu S; Hosoi M; Belcaro G; Dugall M; Feragalli B; Cotellese R; Luzzi R
    Minerva Cardioangiol; 2019 Oct; 67(5):392-398. PubMed ID: 31637898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of a lecithin-based delivery form of boswellic acids (Casperome®) for the prevention of symptoms of irritable bowel syndrome: a randomized clinical study.
    Riva A; Giacomelli L; Togni S; Franceschi F; Eggenhoffner R; Zuccarini MC; Belcaro G
    Minerva Gastroenterol Dietol; 2019 Mar; 65(1):30-35. PubMed ID: 30676012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in signs and symptoms in psoriasis patients with Pycnogenol® supplementation.
    Belcaro G; Luzzi R; Hu S; Cesarone MR; Dugall M; Ippolito E; Corsi M; Caporale S
    Panminerva Med; 2014 Mar; 56(1):41-8. PubMed ID: 24637472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pycnogenol® supplementation in minimal cognitive dysfunction.
    Hosoi M; Belcaro G; Saggino A; Luzzi R; Dugall M; Feragalli B
    J Neurosurg Sci; 2018 Jun; 62(3):279-284. PubMed ID: 29754480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pycnogenol® improves cognitive function, attention, mental performance and specific professional skills in healthy professionals aged 35-55.
    Belcaro G; Luzzi R; Dugall M; Ippolito E; Saggino A
    J Neurosurg Sci; 2014 Dec; 58(4):239-48. PubMed ID: 24675223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behçet syndrome: effects of Pycnogenol® supplementation during regression phases.
    Hu S; Belcaro G; Ledda A; Corsi M; Cotellese R; Feragalli B; Hosoi M; Dugall M; Torino-Rodriguez P; Cesarone MR
    Minerva Cardioangiol; 2018 Aug; 66(4):386-390. PubMed ID: 29975020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pycnogenol® and Centella asiatica in the management of asymptomatic atherosclerosis progression.
    Belcaro G; Ippolito E; Dugall M; Hosoi M; Cornelli U; Ledda A; Scoccianti M; Steigerwalt RD; Cesarone MR; Pellegrini L; Luzzi R; Corsi M
    Int Angiol; 2015 Apr; 34(2):150-7. PubMed ID: 25519846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiopathic myalgic pain (fibromyalgia): supportive management and prevention with Pycnogenol®.
    Belcaro G; Hu S; Cesarone MR; Dugall M; Scipione C; Scipione V; Hosoi M; Ledda A; Cornelli U; Feragalli B; Cotellese R
    Panminerva Med; 2021 Mar; 63(1):46-50. PubMed ID: 33541059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Pycnogenol® on endothelial dysfunction in borderline hypertensive, hyperlipidemic, and hyperglycemic individuals: the borderline study.
    Hu S; Belcaro G; Cornelli U; Luzzi R; Cesarone M; Dugall M; Feragalli B; Errichi B; Ippolito E; Grossi M; Hosoi M; Gizzi G; Trignani M
    Int Angiol; 2015 Feb; 34(1):43-52. PubMed ID: 25391252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supplementation with Pycnogenol® improves signs and symptoms of menopausal transition.
    Errichi S; Bottari A; Belcaro G; Cesarone MR; Hosoi M; Cornelli U; Dugall M; Ledda A; Feragalli B
    Panminerva Med; 2011 Sep; 53(3 Suppl 1):65-70. PubMed ID: 22108479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of common cold with Pycnogenol®: a Winter registry study.
    Belcaro G; Shu H; Luzzi R; Dugall M; Ippolito E; Cesarone MR; Corsi M; Feragalli B
    Panminerva Med; 2014; 56(4):301-8. PubMed ID: 25424463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keloidal penile fibrosis: improvements with Centellicum® (Centella asiatica) and Pycnogenol® supplementation: a pilot registry.
    Ledda A; Cornelli U; Belcaro G; Dugall M; Feragalli B; Cotellese R; Hu S; Corsi M
    Panminerva Med; 2020 Mar; 62(1):13-18. PubMed ID: 32199407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dynamics of indices of visceral sensitivity in patients with irritable bowel syndrome treated with spasmolytics].
    Makarchuk PA
    Eksp Klin Gastroenterol; 2007; (6):126-9. PubMed ID: 18418922
    [No Abstract]   [Full Text] [Related]  

  • 19. Preventive effects of Pycnogenol® on cardiovascular risk factors (including endothelial function) and microcirculation in subjects recovering from coronavirus disease 2019 (COVID-19).
    Belcaro G; Cornelli U; Cesarone MR; Scipione C; Scipione V; Hu S; Feragalli B; Corsi M; Cox D; Cotellese R; Hosoi M; Burki C
    Minerva Med; 2022 Apr; 113(2):300-308. PubMed ID: 34060731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restless legs syndrome: prevention with Pycnogenol® and improvement of the venoarteriolar response.
    Belcaro G; Rohdewald P; Cesarone MR; Scipione C; Scipione V; Cornelli U; Luzzi R; Cotellese R; Dugall M; Hosoi M; Corsi M; Feragalli B
    Panminerva Med; 2022 Jun; 64(2):253-258. PubMed ID: 35815767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.